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Abstract
Background: Elevated total homocysteine (tHcy) levels
are associated with an increased risk of cerebrovascular
disease. It is uncertain whether tHcy is also an indepen-
dent risk factor for cognitive impairment. Methods: We
examined 95 stroke subjects 3 months after their strokes,
and 55 healthy comparison subjects, with a detailed neu-
ropsychological assessment, and MRI brain scans in a
proportion (n = 97). Baseline measurements of tHcy,
serum folate and B12, creatinine and plasma fibrinogen
levels were obtained. Results: tHcy levels were higher in
the stroke subjects by a mean 34%. These levels were
significantly correlated with the first factor of a principal
component analysis of the neuropsychological data, af-
ter controlling for age, folate, B12 and creatinine levels.
The correlation of Hcy levels was particularly significant
with frontal-executive functioning and attention. tHcy
levels were significantly correlated with number of in-
farcts and total stroke volume in the stroke group, but not
with T2-weighted deep white matter hyperintensity
scores, after correction for age. In the control group, tHcy
levels were significantly correlated with ventricle-to-
brain ratios as measures of brain atrophy. Conclusion:
This study provides evidence that high tHcy levels are
associated with cognitive impairment, in particular that
of frontal-executive function. The major component of
this association is accounted for by small and large
strokes, but non-vascular neurotoxic effects of tHcy also
appear to play a role. tHcy must receive greater attention
as a risk factor for cognitive impairment.
Copyright © 2003 S. Karger AG, Basel
Homocysteine (Hcy) is a sulfur-containing amino acid
formed during the metabolism of the essential amino acid
methionine. Elevated plasma homocysteine levels were
first linked with vascular disease by McCully [1]. Recent
studies have confirmed hyperhomocysteinaemia (HHcy)
to be associated with atherosclerotic disease in coronary,
cerebral and peripheral blood vessels [2–4]. While severe
HHcy is rare, mild elevation of blood Hcy levels has been
reported to occur in 5–7% of the general population [5, 6],
30% of patients with coronary artery disease and 42%
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with cerebrovascular disease [7]. In the European Con-
certed Action Project [8], the magnitude of increased risk
for vascular disease associated with HHcy (odds ratio,
OR, for highest to lower quintiles = 2.2) was higher than
that for hypercholesterolemia (OR 1.4), less than that for
hypertension (OR 3.9), and similar to that for tobacco use
(OR 2.2).
A high level of Hcy is both proatherogenic and pro-
thrombotic [7]. Since HHcy is a risk factor for stroke [9,
10], and has been linked with higher rates of microangi-
opathy (i.e. vascular leucoencephalopathy and lacunar
infarctions) [11], it is a risk factor for vascular dementia
[12]. More recently, it has been argued that HHcy may
produce cognitive impairment independently of stroke or
other cerebrovascular disease. Riggs et al. [13] reported a
relationship between Hcy levels and performance on cer-
tain cognitive tests in healthy individuals. Evers et al. [11]
found patients with HHcy to have impairment in cogni-
tive processing as measured by visual event-related poten-
tials. Clarke et al. [14] demonstrated in 164 Alzheimer’s
disease (AD) subjects (76 with autopsy-confirmed AD)
that Hcy levels were elevated and stable over time. In a
study of memory clinic patients [15], Hcy was found to be
an independent predictor of mini-mental state scores. A
recent longitudinal study found plasma Hcy level mea-
sured 8 years earlier to be a strong, independent risk fac-
tor for the development of dementia and AD [16].
If Hcy promotes cognitive impairment and is a risk
factor for AD, it has important epidemiological implica-
tions. In this study, we examined plasma Hcy levels in a
stroke sample to determine if there was an association
between Hcy levels and cognition, and if this could be




Subjects (n = 95) were consecutive patients admitted to two large
teaching hospitals affiliated with the University of New South Wales
who had recently suffered an ischemic stroke as diagnosed by two
neurologists, and who met the diagnostic criteria for cerebral infarc-
tion [17]. Subjects were aged 55–85 years, did not have a diagnosis of
dementia or other neurological disorder prior to the stroke, were not
currently aphasic and were well enough to consent to participate.
Healthy comparison subjects (n = 55) were age-matched, unpaid vol-
unteers recruited from the neighbourhood community who had no
history of stroke or other neurological or psychiatric disorder.
Assessment
Stroke subjects had a baseline assessment within 1 week of admis-
sion which included a detailed medical history and examination, his-
tory of risk factors for cerebrovascular disease and dementia, a func-
tional assessment and the Mini-Mental State Examination [18]. Lab-
oratory measurements included total Hcy (tHcy), serum B12 and
folate levels, creatinine and plasma fibrinogen. Between 3 and 6
months after the stroke, a detailed neuropsychological assessment
was performed and 97 subjects (55 stroke patients and 42 controls)
had a brain MRI scan. The comparison group had a similar assess-
ment performed in one stage.
Homocysteine Measurement
Fasting blood was collected and centrifuged within 6 h, and the
plasma stored at –20 °C for later analysis. Total Hcy was measured
using a fluorescence-based immunochemical technique with demon-
strated high repeatability [19, 20].
Neuropsychological Assessment
Premorbid ability was estimated on the basis of performance on
the National Adult Reading Test [21]. Screening for depression was
carried out as part of the psychiatric assessment, and the Geriatric
Depression Scale [22] was administered. The battery comprised the
following tests pertaining to various cognitive domains: handedness
[23], attention (Wechsler Memory Scale-Revised, WMS-R, Mental
Control Subtest, Wechsler Adult Intelligence Scale-Revised, WAIS-
R, Digit Span subtest) [24]; speed of information processing (Trail
Making Test Part A, Symbol Digit Modalities Test) [25]; verbal
memory (Logical Memory I and II from WMS-R), visual memory
(Visual Reproduction I and II from WMS -R) [26]; language (Modi-
fied Boston Naming Test) [27, 28], Modified Token Test [29], Sen-
tence Repetition [30]; visuospatial and visuoconstructional ability –
copying simple figures [31], clock drawing [30], WAIS-R Block
Design Subtest [24]; arithmetical ability, WAIS-R Arithmetic Sub-
test [24]; gnosis (finger gnosis and stereognosis) [32]; praxis (Western
Aphasia Battery praxis items) [33]; executive function, WAIS-R Sim-
ilarities Subtest [24], Picture Completion Subtest (WAIS-R), Mattis
Dementia Rating Scale Identities and Oddities Subtest [34], Colour
Form Sorting Test [35], verbal generativity (FAS and animals) [36]
and Trail Making Test Part B [37].
MRI Brain Scans
MRI was performed on a proportion of subjects (n = 55 stroke;
n = 42 controls) using a 1.5-T Signa GE magnet and the following
protocol: a scout mid-sagittal cut (2D, TR 300 ms, TE 14 ms; 5 mm
thick, number of excitations 1.5); 1.5-mm-thick T1-weighted contigu-
ous coronal sections through whole brain using a FSPGR sequence
and 3D acquisition (TR 14.3 ms, TE 5.4 ms); 4-mm-thick T2-
weighted FLAIR coronal slices through whole brain (TR 8900, TE
145, TI 2200, FOV 25, 256 ! 192). Fifty-three subjects did not
receive MRI scans because of claustrophobia or unwillingness to
undergo the test.
Analysis of Data
Neuropsychological Tests. Raw scores were converted to age-
scaled scores using published norms [24–26, 28, 36, 38–41]. Com-
posite z-scores were obtained for each domain. The raw scores from
individual tests were also used in the exploratory analyses.
MRI Scans. These were rated by a trained rater with good inter-
rater (Î scores from 0.7 to 0.9 on various measures) and intra-rater
(Î 0.8 to 0.9) reliability determined on five scans each. All ratings
were carried out on a computer console using ANALYZE (Mayo
Foundation) software. Brain infarctions were identified on T1-
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t value (d.f.) p value
Demographics
Age, years 71.7 (6.8) 72.7 (8.6) –0.9 (148) 0.35
Males, % 50.6 56.6 ¯2 = 8.7 !0.001
Education, years 11.7 (3.3) 10.1 (2.6) 3.9 (148) !0.001
NART IQ1 111.9 (7.7) 105.3 (13.3) 4.0 (148) !0.001
Blood testing
tHcy, Ìmol/l 13.2 (4.5) 17.7 (7.2) –4.2 (148) !0.001
Creatinine, mmol/l 0.079 (0.02) 0.092 (0.03) 3.5 (148) 0.001
T4, pmol/l 14.6 (3.1) 17.9 (10.9) –2.5 (142) 0.006
TSH, mU/l 1.5 (1.3) 2.4 (2.9) –2.70 (143) 0.007
B12, pmol/l 324.7 (332.5) 271.8 (153.1) 1.3 (146) 0.188
Folate, nmol/l 20.2 (9.4) 19.4 (9.5) 0.5 (144) 0.639
Neuropsychological summary z-scores4
Attention 1.4 (2.4) –0.8 (3.5) 5.0 (148) 0.001
Executive 1.6 (2.3) –1.0 (3.2) 6.4 (148) 0.001
Memory 0.9 (2.9) –0.6 (3.4) 3.3 (148) 0.001
Language 1.0 (1.8) –0.6 (2.3) 5.3 (148) 0.001
Brain imaging
Total stroke volume, mm3
VBR2 anterior
midsection

















PVH score3 3.3 3.8 –2.0 (95) 0.066
DWMH score3 2.1 3.5 –3.2 (95) !0.001
Internal capsule hyperintensity score3 1.9 3.2 –3.5 (95) !0.001
1 Intelligence quotient based on performance on the National Adult Reading Test [21].
2 Ventricle to brain ratio (see text).
3 Summary ratings of T2-weighted hyperintensities (see text).
4 Summary scores comprise a linear sum of whole group z-scores based on raw scaled scores calculated from indica-
tive individual neuropsychological tests.
weighted images and each infarction delineated manually to obtain
its area, which multiplied by thickness gave the total stroke volume.
Periventricular (PVH) and deep white matter hyperintensities
(DWMH) were rated on a 0–3 scale [42]. For PVH, ratings were per-
formed for the lining of the lateral ventricles (rims) and the frontal
and occipital horns (caps), the sum of which on either side gave the
total PVH score (maximal score = 18). For DWMH rating, the fron-
tal, temporo-parietal and occipital white matter, and the internal
capsules were rated separately, and the scores for both sides added to
give a total DWMH score (maximal score = 24). As a measure of
atrophy, two ventricle-brain ratios (VBR, anterior and midsection)
were obtained as described by Victoroff et al. [43].
Statistical Analysis. The two groups were compared on sociode-
mographic, neuropsychological, brain imaging and laboratory pa-
rameters. tHcy levels were correlated with neuropsychological and
brain imaging parameters, as well as with folate, B12, cholesterol,
fibrinogen and creatinine levels. The relationship of tHcy with age
and gender was examined. The neuropsychological data were sub-
jected to a principal component analysis, and the first factor was cor-
related with tHcy levels, with corrections for age, folate and B12 levels
and creatinine. Linear regression models were used to examine the
independent effects of stroke and white matter hyperintensity char-
acteristics, age and tHcy and to determine the direct and indirect
effects of tHcy on cognition.
Results
Sample Characteristics
The characteristics of the sample are described in
table 1. The two groups were closely matched on age, but
there were significantly more men in the stroke sample
158 Dement Geriatr Cogn Disord 2003;15:155–162 Sachdev et al.









Attention1 –0.26 (0.001) –0.18 (0.19) –0.16 (0.14)
Executive1 –0.29 (0.001) –0.14 (0.33) –0.2 (0.05)
Memory1 –0.26 (0.001) –0.28 (0.04) –0.18 (0.085)
Language1 –0.23 (0.006) –0.21 (0.12) –0.09 (0.407)
Age 0.25 (0.003) 0.40 (0.003) 0.2 (0.057)













Language1 –0.05 (0.576) –0.04 (0.795) 0.08 (0.532)
TMT-A 2 0.23 (0.014) 0.01 (0.949) 0.20 (0.102)
TMT-B3 0.28 (0.003) –0.13 (0.412) 0.30 (0.013)
Probability of zero order and partial correlations is given in
parentheses.
1 Summary scores on cognitive domains, which comprise a linear
sum of whole group z-scores based on raw scaled scores calculated
from indicative individual neuropsychological tests.
2 Trails Making Test A.
3 Trails Making Test B.
(51% in the control group, 57% in the stroke group; ¯2 =
8.7, p ! 0.01). The control group had received, on an aver-
age, 1.6 years more of education (t = 3.9, p ! 0.001) and
had a higher IQ as measured on the National Adult Read-
ing Test (t = 4.0, p ! 0.001).
tHcy levels were significantly higher in the stroke sam-
ple by a mean 34% (t = 4.17, d.f. = 148 , p ! 0.000). 60% of
stroke subjects had a tHcy level of 615 Ìmol/l compared
to 25% of control subjects. For the entire sample, 31% of
stroke and 10% of control subjects were in the upper quar-
tile of tHcy values. tHcy levels were significantly corre-
lated with age (r = 0.25, p = 0.003 for whole group), folate
(–0.21, p ! 0.02) and creatinine (r = 0.59, p = 0.000) lev-
els, but not with B12 levels. The two groups did not differ
significantly on folate or serum B12 levels, but the stroke
group had significantly higher creatinine levels (p =
0.001). tHcy levels were higher in men (17.2 B
6.9 Ìmol/l) compared to women (14.9 B 6.5 Ìmol/l),
but when corrected for age, creatinine and folate levels,
the estimated marginal mean for tHcy in men was
15.8 Ìmol/l and in women 16.1 Ìmol/l (p = 0.78). The
stroke sample performed less well on all domains of neu-
ro-psychological functioning. The stroke sample had high-
er signal hyperintensity scores on T2-weighted MRI in
both the deep white matter and periventricular regions,
but the VBRs were not significantly different for the two
groups. These results are presented in table 1. We com-
pared the subjects who received an MRI scan (n = 97)
with those who did not (n = 53) on age, gender, education
and tHcy levels. There were no significant differences
between the groups.
Hcy and Cognition
The tHcy levels had a significant correlation with all
four domains of cognitive functioning for the entire sam-
ple, and these were also significant after correction for
age, folate and creatinine levels, for the domains of execu-
tive functioning and attention. The correlations suggested
poorer cognitive functioning with higher tHcy levels. This
was confirmed by testing the relationship between tHcy
levels and the first cognitive factor of a principal compo-
nent reduction of the neuropsychological data. Forty-
three percent of cognitive variance was explained by this
first PCA factor (PCA1) alone. When scores on the first
factor were used to divide the entire sample into high and
low cognitive groups, being in the pathological tHcy range
increased odds of membership of the lower cognitive
group by 3.3 times (controlling for age, folate and creati-
nine, OR = 3.27, 95% confidence interval = 1.30–8.24). A
linear association was also found between tHcy and
PCA1: r = –0.30, p = 0.001 after controlling for age, folate,
B12 levels and creatinine. The high and low cognitive
groups were divergent in tHcy distribution (independent
sample t test: t = 2.9, d.f. = 141, p = 0.005).
When examining the two groups separately, tHcy lev-
els were significantly related to executive functioning in
the stroke group and to memory functioning in the control
group. After controlling for age, folate and creatinine lev-
els, the correlation of tHcy with frontal-executive func-
tioning approached significance (table 2). Since the mag-
nitude of the relationship was small (between r = 0.2 and
0.3), sample sizes of individual groups require approxi-
mately 125 subjects to achieve 80% power while testing
significance at the 0.05 level. We examined the relation-
ship of tHcy levels to performance on individual neuro-
psychological tests, and the best correlation was with
Trails B time (r = 0.28, p = 0.003 for the whole group; r =
0.30, p = 0.013 for the stroke group), which was signifi-
cant after controlling for age, folate and creatinine levels.
Furthermore, there was evidence of a graded relation-
ship between tHcy and cognitive performance. The whole
sample was divided into tHcy quartiles and cognitive cor-
relations tested. Table 3 shows that these associations
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Table 3. Graded relationship between Hcy








1 (6–12.0) 0.23 (0.201) –0.12 (0.478) 0.01 (0.973)
2 (12–14.75) 0.18 (0.291) –0.18 (0.273) 0.28 (0.184)
3 (14.75–19.0) 0.36 (0.054*) –0.04 (0.825) –0.14 (0.465)
4 (19.0+) 0.46 (0.008) –0.24 (0.155) 0.013 (0.957)
Relationships marked by * are significant if using one-tailed test.
TMTB = Trail Making Test B Time.
Factor 1 = Neuropsychological Factor 1 score (see text).
DWMHs = Deep white matter hyperintensity score.
Table 4. Zero order and partial
correlations between serum tHcy and









Infarcts 0.43 (!0.001) –0.09 (0.561) 0.30 (0.035)
Total stroke volume 0.24 (0.02) –0.21 (0.192) 0.01 (0.362)
VBR1 anterior 0.14 (0.188) 0.44 (0.003) 0.03 (0.825)
midsection 0.20 (0.05) 0.49 (0.001) 0.01 (0.940)
Whole brain hyperintensity score2 0.2 (0.05) –0.01 (0.940) 0.15 (0.269)
PVH score2 0.16 (0.123) 0.041 (0.798) 0.14 (0.309)
DWMH score2 0.22 (0.033) –0.01 (0.940) 0.16 (0.250)
Internal capsule hyperintensity score2 0.23 (0.022) 0.04 (0.798) 0.15 (0.275)
Controlling for age, folate and creatinine
VBR1 anterior
midsection










p values are given within parentheses.
* All correlations are Pearson’s except for number of infarcts, for which Spearman’s Ú was
used.
1 Ventricle to brain ratio (see text).
2 Summary ratings of T2-weighted hyperintensities (see text).
were strongest in the highest tHcy quartile and absent in
the physiological range.
Mechanism of the Relationship
The mechanism of the relationship between tHcy and
cognition was explored by examining its association with
neuroimaging parameters (table 4). tHcy had a significant
correlation with number of infarcts (Spearman’s Ú = 0.3,
p = 0.04) in the stroke group. To determine if tHcy con-
centration was related to individual stroke size, the aver-
age stroke volume was categorized into quintiles. The cat-
egories did not differ significantly in mean tHcy concen-
trations, suggesting that the association of tHcy was with
stroke number and not size. The correlation with DWMH
score was significant (r = 0.23, p = 0.04) for the entire
group, but this was not significant after correcting for age
and gender. There was a weak association between tHcy
and VBR, midsection, in the whole group (r = 0.21, p =
0.07). When the groups were examined separately, there
was a strong age, gender, folate and creatinine invariant
relationship between tHcy and VBR for the control group
only (r = 0.54, p = 0.002). The best neuroimaging corre-
lates of cognitive performance (factor 1 scores) were
DWMH ( r = –0.40, p = 0.000), stroke number (r = –0.45,
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p = 0.000) and stroke volume (r = –0.47, p = 0.000). Each
of these was significant after adjusting for age and gender.
Only DWMH was associated with TMT-B performance
independent of age and Hcy levels. A comparison of the
high and low cognitive performance groups, divided into
two halves on the basis of their PCA1 scores, of the bio-
chemical, neuroimaging and neurochemical parameters
showed that the low cognitive group had higher tHcy lev-
els (17.3 Ìmol/l cf. 14.4 Ìmol/l, t = 2.7, p = 0.007) as well
as more T2-weighted hyperintensities (OR = 2.46, p !
0.001).
A multiple regression analysis showed that there was a
small direct effect of tHcy on cognition in the stroke group
(ß = –0.017, p = 0.08) when age, stroke number, stroke
volume and WMH scores had been accounted for.
Discussion
Elevated tHcy levels have been associated with cere-
brovascular disease in a large number of studies. In a
recent meta-analysis of the literature, which included
eight cross-sectional and four longitudinal studies, Moller
et al. [10] reported that with tHcy levels higher than the
95th percentile, the OR of cerebrovascular disease was
3.97. Our study supports an association of mild HHcy
with stroke, with our stroke subjects having elevated
mean tHcy levels compared with control subjects. Low
serum folate and B12 levels, high creatinine levels or age of
subjects could not account for these elevated levels.
HHcy has been more closely linked with microvascular
rather than macrovascular brain disease [44]. It is impor-
tant to note the characteristics of our stroke patients. The
mean volume of infarcted tissue on T1-weighted MRI,
performed 3–6 months after the stroke, was 1.5 ml, sug-
gesting that the majority of our subjects had small strokes.
Some of the control subjects (n = 4, 5%) also had ‘silent’
lacunar infarcts, with a mean volume of infarction in this
group being 0.052 ml. All subjects had some degree of
small vessel disease as evidenced by white matter lesions
on MRI. For this reason, we pooled the data from the two
groups for some of the associations. Our subjects did not
show a significant relationship between tHcy levels and
ratings of DWMHs after correction for age. This is in con-
trast with Fassbender et al. [44] and Evers et al. [11] who
reported an association of high Hcy levels with microan-
giopathy. There was however a significant relationship
with VBR as a marker of cerebral atrophy, especially in
the control group, which was independent of the covar-
iates examined (folate and creatinine levels and age). This
result has been previously reported [45]. Since many of
the correlations examined using the entire sample were in
the range of 0.2–0.3, we cannot rule out the possibility of
false-negative results because of a small sample size for
the individual groups. With this type of association, a
power estimate for the stroke group was approximately
0.77.
There are a number of limitations of our data. First,
this is a cross-sectional study, from which only plausible
conclusions can be drawn about the direction of causality,
that must be further examined in a longitudinal design.
Second, the sampling for tHcy was performed within 1–2
weeks of the stroke, whereas the MRI was performed
about 4 months later. Since none of the subjects had a
further stroke in the intervening period, it is likely that the
MRI scan at 4 months would accurately reflect the cere-
brovascular disease at baseline. We were unable to repeat
the tHcy levels at 4 months, which would establish a more
stable tHcy level in these subjects. It is possible that our
measurements of tHcy were affected by an acute phase
reaction. It has been reported that tHcy levels have an
acute phase reduction and possibly a post-acute phase
increase for different reasons [46]. An acute phase reduc-
tion would, however, have produced a result opposite to
the one we report in our paper. It therefore does not weak-
en the findings of this study. Third, the sample size was
modest for some of the associations, such that some asso-
ciations were significant for the entire sample but not so
when groups were examined separately. We justify pool-
ing the subjects for examining some of the associations
because of shared features such as DWMHs, silent strokes
and brain atrophy, and the observation that trends were
similar in the two groups. For such analyses, we ac-
counted for infarcts in the brains of the stroke patients.
Fourth, the control sample was not a random community
sample. However, we tried to recruit controls from the
same neighbourhood as the patients. The lack of matching
on gender and baseline intellectual functioning was dealt
with by using these two variables as covariates in the anal-
yses. Fifth, not all subjects had MRI scans because of refu-
sals or ineligibility, dealt with by restricting the regression
analyses to a limited number of variables, as suggested by
the preliminary analyses. We compared the subjects with
and without MRIs on sociodemographic and neuropsy-
chological variables, on which they did not differ statisti-
cally, arguing against a biased selection of subjects for
MRI.
The most notable finding of our study is the relation-
ship between cognitive functioning and tHcy levels. These
were significant for the entire group for executive func-
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tioning and memory, after correction for age, and folate,
vitamin B12 and creatinine levels. In fact, when the rela-
tionship with individual tests was examined, it was stron-
gest with the time taken to complete Trails B [37], which
was significant for the stroke group as well as the entire
sample. In addition to being a visuomotor tracking task,
this test examines the ability of the individual to shift set
from one sequence to the other, and is very sensitive to
brain damage with disturbance in frontal-executive func-
tioning. In our sample, performance on Trails B corre-
lated significantly with PVH and DWMH scores, suggest-
ing that white matter disease may be one mediating factor
in this relationship. However, that does not entirely
explain the relationship between elevated tHcy levels and
test performance, as indicated by the regression analysis,
and other effects of Hcy on cognition should be consid-
ered.
There has been a recent interest in the role HHcy may
play in neurodegeneration. The relationship between Hcy
levels and cognitive impairment has been reported in two
large epidemiological studies of healthy subjects [13, 47],
with the association not being accounted for by low vita-
min B12, B6 or folate levels. In the study by Riggs et al.
[13], Hcy was found to correlate with performance on a
spatial copying task. Recently, three case-control studies
[14, 15, 48] and one prospective study [16] have reported
a relationship between high Hcy levels and AD. These
findings suggest that the impact of Hcy on cognition may
not be exclusively mediated through vascular disease. Our
finding of the relationship with cognitive functioning
which could not be accounted for by low vitamin levels or
MRI-documented vascular disease supports this conclu-
sion. Further support for this comes from the relationship
between tHcy levels and brain atrophy in the control sam-
ple. Of course, it is possible that Hcy is related to micro-
vascular disease that is not detected by T2-weighted MRI,
and neuropathological examination is necessary to deter-
mine this.
The association of Hcy with cognitive deficits does not
necessarily imply that HHcy causes the impairment. The
possibility that cognitive impairment led to vitamin defi-
ciency and a secondary rise in Hcy levels in these patients
was, however, considered unlikely. None of the subjects
was deficient in folate and B12, and we did not see a signif-
icant correlation between Hcy and vitamin B12 levels. The
mechanism by which Hcy may cause cognitive impair-
ment not mediated through vascular disease is not under-
stood, but a number of possibilities have been suggested
[49]. Hcy has been reported to be directly neurotoxic
through its action on the N-methyl-D-aspartate glutamate
receptor [50], and its metabolite homocysteic acid is also
excitotoxic [51]. Exposure of rat hippocampal neurons to
Hcy has been shown to lead to activation of poly-ADP-
ribose polymerase and NAD depletion, which precede
mitochondrial dysfunction, oxidative stress, caspase acti-
vation and neuronal apoptosis [46]. It is also possible that
Hcy-related microvascular disease increases the deposi-
tion of ß-amyloid plaques and neurofibrillary tangles that
are associated with AD.
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